SHAREHOLDERS’ EQUITY | Transaction with Synchron On August 18, 2017, the Company and General Atomics Uranium Resources, LLC, executed a term sheet for the purchase of common shares of the Company and the grant of an option to purchase common shares, and intellectual property rights (the “Term Sheet”). The Term Sheet provided that, upon the terms and subject to the conditions set forth in the Term Sheet, among other things, (i) General Atomics Uranium Resources, LLC or one or more of its affiliates (“General Atomics”) would pay $500 in cash (the “Preliminary Payment”) to the Company within three business days of the execution of the Term Sheet; (ii) the Company and General Atomics would enter into an investment agreement (the “Investment Agreement”), an option agreement (the “Option Agreement”) and an intellectual property rights Agreement (the “IP Rights Agreement), all discussed below, for gross proceeds of $4,752 in cash, less the Preliminary Payment, at the closing of the transaction. On October 2, 2017, the Company and Synchron, a subsidiary of General Atomics Technologies Corporation (“Synchron”), completed the transaction in accordance with the following terms. Pursuant to an Investment Agreement the Company: (i) issued to Synchron 26,650,000 common shares of the Company (the “Acquired Shares”), which constituted approximately 33.5% of the issued and outstanding common shares of the Company; (ii) received gross proceeds of $4,752 in cash less the Preliminary Payment; and (iii) granted Synchron an option (the “Option”) to purchase approximately an additional 15.49% of the Company’s fully diluted common shares immediately after the exercise for an aggregate exercise price of an additional $5,040. Synchron’s ownership percentage, immediately after giving effect to such exercise, is limited to 49.9% of the Company’s common shares issued and outstanding. The Option is exercisable for a period up to four years from the initial investment. Additionally, the parties executed an IP Rights Agreement, whereby Synchron received rights to use and improve the Company’s intellectual property relating to our patents-pending and related technical information. The Company made customary representations and warranties in the Investment Agreement. The representations and warranties of the parties survive the closing of the transactions contemplated by the Investment Agreement until the earliest to occur of (i) the fourth anniversary of such closing and (ii) the exercise date of the Option. Pursuant to and subject to the terms and conditions of the Investment Agreement, Synchron is entitled to nominate two directors for appointment or election to the Company’s Board of Directors, where the Board is comprised of six or seven directors following such appointment. If the Option is exercised in full and Synchron continues to own the Acquired Shares, then Synchron is entitled to nominate one additional director for appointment or election to the Company’s Board of Directors. On November 17, 2017, two Synchron designees were appointed to the Company’s Board of Directors. Pursuant to and subject to the terms and conditions of the Investment Agreement, absent a waiver approved by the Company’s Board of Directors with the concurrence of a majority of Synchron’s director designees, the Company may not take the following major actions without the approval of the holders of a majority of the common shares then outstanding: (i) authorizing the issuance of additional shares of capital stock of the Company; (ii) incurring indebtedness in excess of $1,000; (iii) entering into any transaction or series of related transactions involving the acquisition of any assets or equity interests or the disposition of the Company’s assets, in each case involving consideration in excess of $1,000; or (iv) authorizing any dividend or distribution. In addition, pursuant to and subject to the terms and conditions of the Investment Agreement, Synchron has (A) the right to purchase its pro rata share of any common shares that are issued by the Company in connection with any financing, (B) certain customary piggyback registration rights for the common shares of the Company held by Synchron and (C) certain information and indemnification rights. Pursuant to the IP Rights Agreement, Synchron and its affiliates were granted certain rights to the Company’s intellectual property relating to our patents-pending and related technical information. Subject to the terms and conditions of the IP Rights Agreement, Synchron and its affiliates were granted a perpetual non-exclusive license in the Company’s intellectual property which, upon exercise of the Option, will become exclusive to Synchron and its affiliates, subject to all rights in the intellectual property retained by the Company. The Company made certain representations and warranties as to the current status of its intellectual property at the time of the license grant. In addition, pursuant to and subject to the terms and conditions of the IP Rights Agreement, Synchron (i) will receive a royalty-free exclusive right to the Company’s rare earth intellectual property if the Option is exercised in full but (ii) will be required to pay a commercially reasonable royalty to the Company for its intellectual property if Synchron does not exercise the Option prior to its expiration. The Company engaged a third-party valuation firm to determine the fair value of each component of the transaction: the Investment Agreement, the Option Agreement and the IP Rights Agreement. As of the close of the transaction, the gross value of each component was determined to be as follows: Investment Agreement $2,900, Option Agreement $825 and the IP Rights Agreement $1,027. The costs incurred to complete the transaction were allocated to each component based on relative fair value to cost of equity, operating expenses and reduction to deferred income as they related to each component, respectively. The value of the common shares was determined using a Probability-Weighted Expected Return Method (“PWERM”) analysis, which included six different probability weighted scenarios based on the calculated enterprise value of the Company utilizing assumptions from the pre-feasibility study completed in 2014 and current rare earth pricing in a discounted cash flow analysis. Due to the variability in the number of common shares that may be issued upon exercised of the Option Agreement, the Option Agreement is considered a derivative liability, as a result we revalue the option liability at the end of each reporting period, until the Option is exercised or expired. Any gains or losses from the revaluation are recorded to the Consolidated Statements of Operations. The fair value of the Option Agreement as of December 31, 2017 was $616. Gain on the revaluation of the option liability was $209 for the year ended December 31, 2017. The Option was valued at the date of the transaction utilizing the Black-Scholes valuation model on October 2, 2017 and December 31, 2017. The significant assumptions are as follows: October 2, 2017 December 31, 2017 Risk-free interest rate 1.79% 2.06% Expected volatility 75% 75% Expected dividend yield Nil Nil Expected term in years 4.0 3.8 Estimated forfeiture rate Nil Nil Estimated exercise price $0.34 $0.34 Estimated enterprise value per common share $0.11 $0.07 The incremental difference between the estimated value of the exclusive and non-exclusive IP Rights Agreement was added to the value from the Black-Scholes value to arrive at the total value of the option. Because Synchron will obtain exclusive rights to the intellectual property if it exercises the Option, the value of the IP Rights Agreement is considered deferred income as the Company retains title to the rare earth intellectual property until Synchron exercises the Option. We amortize the deferred income using the straight-line method over a period of four years (the term of the option agreement) as this is the period of the Company’s performance obligation related to the IP Rights Agreement. During the year ended December 31, 2017, we amortized $64 of deferred intellectual property income. The value of the IP Rights Agreement was determined using a PWERM analysis for six different probability weighted scenarios using the relief from royalty method based on market royalty rates for similar agreements. Stock-based Compensation We have options outstanding and exercisable that were issued under the . The terms of the RSOP were approved by our shareholders at the annual meeting of shareholders on December 2, 2011. The RSOP established the maximum number of common shares which may be issued under the RSOP as a variable amount equal to 10% of the issued and outstanding common shares on a non-diluted basis. Under the RSOP, our Board of Directors may from time to time grant stock options to individual eligible directors, officers, employees or consultants. The maximum term of any stock option is 10 years. The exercise price of a stock option is not less than the closing price on the last trading day preceding the grant date. The Board retains the discretion to impose vesting periods on any options granted The fair value of stock option awards granted to directors, officers, employees and/or consultants of the Company are estimated on the grant date using the Black-Scholes option valuation model and the closing price of our common shares on the grant date. The significant assumptions used to estimate the fair value of stock option awards using the Black-Scholes option valuation model are as follows: For the years ended December 31, 2017 2016 Risk-free interest rate 0.8 – 2.0% 1.9% Expected volatility 113 – 133% 91 – 109% Expected dividend yield Nil Nil Expected term in years 5.0 5.0 Estimated forfeiture rate Nil Nil The following table summarizes stock option activity for each of the years ended December 31, 2017 and 2016: For the years ended December 31, 2017 2016 Number of Stock Options Weighted Average Exercise Price Number of Stock Options Weighted Average Exercise Price Outstanding, beginning of period 3,694,900 $4.61 4,578,700 $4.61 Granted 900,000 0.23 1,600,000 0.04 Cancelled/Expired (563,500) 1.34 (2,483,800) 6.12 Outstanding, end of period 4,031,400 $0.44 3,694,900 $0.94 Exercisable, end of period 3,281,400 $0.49 3,232,400 $1.06 A summary of stock option activity as of December 31, 2017 and changes during the year then ended are presented below. Non-vested Stock Options Number Outstanding Weighted Average Grant Date Fair Value Non-vested at December 31, 2016 462,500 $ 0.03 Granted 900,000 Vested (612,500) Non-vested at December 31, 2017 750,000 $ 0.25 The stock-based compensation cost recognized in our Consolidated Statements of Operations for the years ended December 31, 2017 and 2016 was $33 and $97, respectively. As of December 31, 2017, there was $137 of unrecognized compensation cost related to 750,000 unvested stock options. This cost is expected to be recognized over a weighted-average remaining period of approximately 1.5 years. At December 31, 2017, the intrinsic value of outstanding and exercisable stock options was $297. Warrants Each outstanding warrant is exercisable for one of the Company’s common shares and was issued to investors in connection with the registered direct offering of the Company that closed on April 29, 2015. In addition, the Company issued warrants to a placement agent in connection with the offering, under the same terms as those issued to investors. The exercise price and exercise period of the warrants are outlined below: Financing Investor Warrants Placement Agent Warrants Total Warrants Exercise Price per Share Expiration Date April 29, 2015 offering 2,615,385 261,539 2,876,924 $0.85 4/29/18 The value of the warrants issued to the placement agent (non-employee) for its services in connection with the April 29, 2015 offering was offset against the proceeds of the financing. On September 27, 2016, 1,472,557 warrants that were issued as part of the September 27, 2013 registered direct offering of the Company expired unexercised. The following table summarizes activity for warrants for the years ended December 31, 2017 and 2016: For the year ended December 31, For the year ended December 31, 2016 2017 Number of Options and Warrants Weighted-Average Exercise Price (USD$) Number of Options and Warrants Weighted-Average Exercise Price (USD$) Outstanding, beginning of period 2,876,924 $ 0.85 4,349,481 $ 1.97 Expired – – 1,472,557 4.15 Outstanding, end of period 2,876,924 $ 0.85 2,876,924 $ 0.85 |